Researchers are continually developing new drugs to treat MBC and understanding how to best use drugs already approved for MBC. An important question in treatment planning is the order in which drugs are given, called “drug sequencing”. For example, two antibody-drug conjugates are available for hormone receptor-positive MBC, and clinicians are beginning to understand which one should be given first. The best order in which drugs should be given may be determined by studying medical records to understand the response to treatment when receiving drugs in one order compared to another order.
Click the links below for expert opinions on what drugs should be given in what order and to which patients.
Introduction to the Importance of Drug Sequencing in MBC
- Lillie Shockney, RN: Lillie Shockney, RN comments on the importance of drug sequencing in MBC
- Sara Tolaney, MD (video): Dr. Sara Tolaney discusses sequencing of antibody-drug conjugates in HR+ MBC
- Dr. Sara Sammons and Dr. Nancy Lin (article and video): Dr. Sara Simmons and Dr. Nancy Lin discuss drug sequencing for HER2+ MBC including in people with and without brain metastasis
- Dr. Shridar Ganesan and Dr. Kelly McCann: Dr. Shridar Ganesan and Dr. Kelly McCann report that drug sequencing for HER2+ MBC should be personalized for the patient
Impact on Cost and Quality of Life
- Dr. Stephanie Wheeler: Choosing the best order in which drugs are given reduces cost of treating MBC while preserving quality of life
MBC Clinical Trials
- Metastatic Trial Search: Trials for Treatment Decision Support
- Metastatic Trial Search: Trials for Predicting Response to Treatment
Last Modified on January 31, 2024